VH-298 is primarily used as a potent and selective inhibitor of the von Hippel-Lindau (VHL) protein, which plays a key role in the regulation of hypoxia-inducible factors (HIFs). By inhibiting VHL, VH-298 stabilizes HIF-α subunits, leading to activation of hypoxia-responsive genes. This mechanism is leveraged in research settings to study cellular responses to hypoxia, particularly in cancer biology and ischemic disease models. It is also employed in targeted protein degradation studies, especially in the development and validation of PROTACs (proteolysis-targeting chimeras), where VHL is used as an E3 ubiquitin ligase recruiter. VH-298 helps modulate VHL activity to fine-tune degradation efficiency of target proteins, making it a valuable tool in chemical biology and drug discovery. Due to its cell permeability and reversible binding, VH-298 is useful in both in vitro and cellular assays aimed at understanding oxygen-sensing pathways and for optimizing degrader molecules in preclinical research.